Skip to main content
European Commission logo print header

GluCl as an epileptic seizure autoregulatory Gene therapeutic approach

Objectif

This Horizon2020 – Marie Sklodowska Curie Actions – Individual Fellowship grant proposal focuses on the development of a new gene therapy approach targeting intractable epilepsy, with the major aim to achieve autoregulation of seizure detection and termination. For this purpose, a glutamate-gated chloride channel (GluCl; cloned from C. elegans) will be expressed in excitatory neurons in the rodent brain using a viral vector and a human CamKIIα promoter. In response to increased glutamate levels, as present during epileptic seizures, the channel activates and opens a Cl- conductance. This, in turn, inhibits excitatory neurons and causes seizure suppression. As a further advantage, an “add-on” therapeutic approach with the GluCl agonist ivermectin, an approved antihelminthic drug, is available. In principle, the gene therapy could therefore confer both an autoregulatory effect to the transduced brain region and have an external “gain control” exerted by pharmacological modulation.
Taken together, my Fellowship proposal aims to develop a radically new antiepileptic strategy to treat drug-resistant, refractory epilepsy, which affects approximately 1 million people in Europe.

Régime de financement

MSCA-IF-EF-ST - Standard EF

Coordinateur

UNIVERSITY COLLEGE LONDON
Contribution nette de l'UE
€ 137 591,10
Adresse
GOWER STREET
WC1E 6BT London
Royaume-Uni

Voir sur la carte

Région
London Inner London — West Camden and City of London
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
€ 137 591,10